KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $24.3 million.

  • Aquestive Therapeutics' Operating Expenses rose 1124.04% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.2 million, marking a year-over-year increase of 2398.04%. This contributed to the annual value of $88.3 million for FY2024, which is 3447.82% up from last year.
  • According to the latest figures from Q3 2025, Aquestive Therapeutics' Operating Expenses is $24.3 million, which was up 1124.04% from $21.4 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Operating Expenses registered a high of $28.1 million during Q1 2025, and its lowest value of $15.4 million during Q3 2023.
  • In the last 5 years, Aquestive Therapeutics' Operating Expenses had a median value of $21.4 million in 2025 and averaged $21.2 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Operating Expenses tumbled by 3295.42% in 2023, and later soared by 4865.92% in 2024.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' Operating Expenses stood at $22.7 million in 2021, then dropped by 5.94% to $21.4 million in 2022, then dropped by 20.0% to $17.1 million in 2023, then soared by 48.66% to $25.4 million in 2024, then decreased by 4.56% to $24.3 million in 2025.
  • Its Operating Expenses was $24.3 million in Q3 2025, compared to $21.4 million in Q2 2025 and $28.1 million in Q1 2025.